Vaccines and Global Health: The Week in Review
20 May 2023 :: Issue 704
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf:  If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents  [click to move among sections]
:: Coronavirus [COVID-19]
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Milestones, Perspectives

Seventy-sixth World Health Assembly  #WHA76
Geneva, Switzerland, 21–30 May 2023

Webcast
Proceedings will be webcast live from this web page. Simultaneous interpretation is available in Arabic, Chinese, English, French, Russian and Spanish.

Key documents
Provisional agenda - 4 April 2023
Preliminary Journal - 5 May 2023
Journal No. 1 - 21 May 2023

Documents
All WHA76 documents
Selected Documents
A76/8 - Public health emergencies: preparedness and response
   The Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme
A76/9 Rev.1 - Implementation of the International Health Regulations (2005)
A76/10 - Strengthening WHO preparedness for and response to health emergencies
   Strengthening the global architecture for health emergency preparedness, response and resilience
A76/11 - WHO’s work in health emergencies
   Public health emergencies: preparedness and response
A76/12 - Implementation of resolution WHA75.11 (2022)
A76/13 - Poliomyelitis
   Poliomyelitis eradication
A76/14 - Poliomyelitis
   Polio transition planning and polio post-certification

Media Release
Seventy-sixth World Health Assembly to focus on “saving lives, driving health for all” as WHO turns 75
19 May 2023

...This year’s session of the World Health Assembly will determine the immediate and longer-term future of WHO, starting with the program budget for the next two years, key decisions about the sustainable financing of the Organization and changes put in place to improve WHO’s processes and accountability. Delegates will also deliberate about the critical role that WHO has in the Global Health Emergency Architecture.

The backdrop to these issues is the organization’s 75th anniversary, with the highlights of its collective global health achievements since WHO’s creation in 1948. It will review last year’s progress, accomplishments and challenges along with future priorities across the key pillars of WHO’s work: Universal Health Coverage, Emergencies, Promoting Health and Well-being. WHA76 will convene 21-30 May at the Palais des Nations in Geneva.
“As we mark WHO's 75th anniversary, we can be proud of our past achievements, but we must be mindful of lessons learned, as we transition from the emergency phase of COVID-19, and create a future where every person has access to the health services they need,” said Director-General Dr Tedros Adhanom Ghebreyesus. "This means strengthening the global architecture for health emergency preparedness, response and resilience, supporting countries on the road to universal health coverage, and building a stronger, sustainably-funded and accountable WHO."

**Key discussions and decisions are expected on:**
- A review of WHO's work in health emergencies, including the International Health Regulations and strengthening WHO preparedness for and response to health emergencies;
- Strategies and global action on areas such as women’s, children’s and adolescents’ health, rehabilitation, universal health coverage and primary health care, traditional medicine, infection prevention and control, substandard and falsified medicines, health of refugees and migrants, non-communicable diseases, mental health, social determinants, nutrition and disabilities;
- Approval of the WHO Programme Budget for 2024-2025, including the decision to increase assessed contributions and other matters emanating from the Working Group on Sustainable Financing...

::::::

**WHO launches global network to detect and prevent infectious disease threats**

20 May 2023

WHO and partners are launching a global network to help protect people from infectious disease threats through the power of pathogen genomics. The International Pathogen Surveillance Network (IPSN) will provide a platform to connect countries and regions, improving systems for collecting and analyzing samples, using these data to drive public health decision-making, and sharing that information more broadly.

Pathogen genomics analyzes the genetic code of viruses, bacteria and other disease-causing organisms to understand how infectious they are, how deadly they are, and how they spread. With this information, scientists and public health officials can identify and track diseases to prevent and respond to outbreaks as part of a broader disease surveillance system, and to develop treatments and vaccines.

The IPSN, with a Secretariat hosted by the WHO Hub for Pandemic and Epidemic Intelligence, brings together experts worldwide at the cutting-edge of genomics and data analytics, from governments, philanthropic foundations, multilateral organizations, civil society, academia and the private sector. All share a common goal: to detect and respond to disease threats before they become epidemics and pandemics, and to optimize routine disease surveillance.

The goal of this new network is ambitious, but it can also play a vital role in health security: to give every country access to pathogen genomic sequencing and analytics as part of its public health system,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “As was so clearly demonstrated to us during the COVID-19 pandemic, the world is stronger when it stands together to fight shared health threats.”...

::::::
WHO - Urgent action needed to tackle stalled progress on health-related Sustainable Development Goals
19 May 2023
WHO is releasing the 2023 edition of its annual World Health Statistics report with new figures on the impact of COVID-19 pandemic and the latest statistics on progress towards the health-related Sustainable Development Goals (SDGs).

The report with data up to 2022 underscores a stagnation of health progress on key health indicators in recent years compared with trends seen during 2000-2015. It also alerts us to the growing threat of noncommunicable diseases (NCDs) and climate change, and calls for a coordinated and strengthened response.

COVID-19 cost in lost lives and health progress
The report documents updated statistics on the toll of the pandemic on global health, contributing to the ongoing decline in progress towards the SDGs. During 2020-2021, COVID-19 resulted in a staggering 336.8 million years of life lost globally. This equates to an average of 22 years of life lost for every excess death, abruptly and tragically cutting short the lives of millions of people.

Since 2000, we saw significant improvements in maternal and child health with deaths falling by one-third and one-half, respectively. The incidence of infectious diseases such as HIV, tuberculosis (TB) and malaria also declined, along with a lowered risk of premature deaths from NCDs and injuries. Together, these contributed to an increase in global life expectancy from 67 years in 2000 to 73 years in 2019.

However, the pandemic has put many health-related indicators further off-track and contributed to inequalities in access to high-quality health care, routine immunizations and financial protection. As a result, improving trends in malaria and TB have been reversed, and fewer people were treated for neglected tropical diseases (NTDs).

“The World Health Statistics is WHO’s annual check-up on the state of the world’s health. The report sends a stark message on the threat of noncommunicable diseases, which take an immense and increasing toll on lives, livelihoods, health systems, communities, economies and societies,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “The report calls for a substantial increase in investments in health and health systems to get back on track towards the Sustainable Development Goals.”...

WHO calls for safe and ethical AI for health
16 May 2023
The World Health Organization (WHO) is calling for caution to be exercised in using artificial intelligence (AI) generated large language model tools (LLMs) to protect and promote human well-being, human safety, and autonomy, and preserve public health.

LLMs include some of the most rapidly expanding platforms such as ChatGPT, Bard, Bert and many others that imitate understanding, processing, and producing human communication. Their meteoric
It is imperative that the risks be examined carefully when using LLMs to improve access to health information, as a decision-support tool, or even to enhance diagnostic capacity in under-resourced settings to protect people’s health and reduce inequity.

While WHO is enthusiastic about the appropriate use of technologies, including LLMs, to support health-care professionals, patients, researchers and scientists, there is concern that caution that would normally be exercised for any new technology is not being exercised consistently with LLMs. This includes widespread adherence to key values of transparency, inclusion, public engagement, expert supervision, and rigorous evaluation.

Precipitous adoption of untested systems could lead to errors by health-care workers, cause harm to patients, erode trust in AI and thereby undermine (or delay) the potential long-term benefits and uses of such technologies around the world.

Concerns that call for rigorous oversight needed for the technologies to be used in safe, effective, and ethical ways include:
- the data used to train AI may be biased, generating misleading or inaccurate information that could pose risks to health, equity and inclusiveness;
- LLMs generate responses that can appear authoritative and plausible to an end user; however, these responses may be completely incorrect or contain serious errors, especially for health-related responses;
- LLMs may be trained on data for which consent may not have been previously provided for such use, and LLMs may not protect sensitive data (including health data) that a user provides to an application to generate a response;
- LLMs can be misused to generate and disseminate highly convincing disinformation in the form of text, audio or video content that is difficult for the public to differentiate from reliable health content; and
- while committed to harnessing new technologies, including AI and digital health to improve human health, WHO recommends that policy-makers ensure patient safety and protection while technology firms work to commercialize LLMs.

WHO proposes that these concerns be addressed, and clear evidence of benefit be measured before their widespread use in routine health care and medicine – whether by individuals, care providers or health system administrators and policy-makers.

WHO reiterates the importance of applying ethical principles and appropriate governance, as enumerated in the WHO guidance on the ethics and governance of AI for health, when designing, developing, and deploying AI for health. The 6 core principles identified by WHO are: (1) protect autonomy; (2) promote human well-being, human safety, and the public interest; (3) ensure transparency, explainability, and intelligibility; (4) foster responsibility and accountability; (5) ensure inclusiveness and equity; (6) promote AI that is responsive and sustainable.
AU-Africa CDC-Gavi

**Signing of a new agreement to drive vaccine impact in Africa**


The MoU was signed on behalf of the African Union Commission Chairperson by the AU Commissioner for Health, Humanitarian Affairs & Social Development (HHS) H.E. Amb. Minata Samate Cessouma and Africa Centre for Disease Control and Prevention (Africa CDC) Director General Dr Jean Kaseya, and Gavi Chief Executive Officer Dr Seth Berkley.

The partnership builds on the historic [Addis Declaration on Immunization (ADI)](https://www.gavi.org/addis-declaration-on-immunization) which aims to ensure that everyone in Africa – regardless of who they are or where they live – receives the full benefits of immunization. It includes 10 commitments to increase political, financial and technical investments in immunization programs. The evolving direction of this partnership is bound to accelerate the attainment of health security as premised in the AU Agenda 2063 and the [New Public Health Order (NPHO)](https://www.africa-union.org/press-releases/au-africa-cdc-gavi-signing-of-a-new-agreement-to-drive-vaccine-impact-in-africa).

Through this MoU, AUC and Gavi commit to work together to:

1. Scale up and strengthen routine immunization, focusing on reaching “zero dose” children – children that have not received a single dose of a routine vaccine;
2. Build sustainable regional vaccine manufacturing in Africa;
3. Undertake joint advocacy to boost vaccine demand for routine vaccines;
4. Strengthen primary health care systems and bolster diagnostic and surveillance capacity for diseases such as yellow fever, cholera, and typhoid;
5. Communicate jointly on routine immunization, pandemic prevention, preparedness and response (PPR), vaccine access and delivery;

The AUC and Africa CDC, in April 2021, established the Partnerships for African Vaccine Manufacturing (PAVM) to steer a bold goal that will enable the African vaccine manufacturing industry to develop, produce, and sustainably increase supply, from less than 1 percent, currently. This goal can be reached through achieving sustainable and reliable economies of scale by launching mechanisms that create demand certainty for manufacturers while facilitating country procurement. The AU Bureau of Heads of State and Government further requested Gavi and other partners to procure a percentage of all vaccines produced by the continent.

In December 2022, the Gavi Board approved a plan to support the development of a regionally diversified vaccine manufacturing ecosystem, based on three pillars: support for strategic antigen selection by manufacturers/countries, market shaping and demand creation. The initiative, supported by the African Union, Africa CDC, G7 and other stakeholders, also envisages the possibility of a fourth pillar, the design of a new financial instrument in the form of an Advance Market Commitment (AMC) for African vaccine manufacturing...

::::::

::::::
**PHEIC**

**Polio**

**Polio this week as of 17 May 2023 - GPEI**

*Headlines [Selected]*

- G7 Health Ministers reaffirm support to polio eradication – Meeting in Nagasaki, Japan, on 13-14 May 2023, Global health leaders commend polio value for broader public health emergencies and call for strengthened support to achieve polio-free world. [Read more...](#)
- The WHO World Health Assembly (WHA) will convene next week in Geneva, Switzerland. While much of the deliberations will focus on the ongoing and evolving COVID-19 situation, the global effort to eradicate polio will also be discussed by Member States. To this effect, the Secretariat has prepared two reports which will inform Member State discussions, namely on polio eradication and on polio transition planning and post-certification.
- GPEI’s 35th Anniversary: From Polio to Progress – here is a recording of a high-level influencer briefing with polio experts from around the world. “We are seeing a level of progress in Afghanistan and Pakistan that is unprecedented: extreme geographic restriction of transmission that gives us the best opportunity we have had to fully stop transmission of polio.” Dr Hamid Jafari, Director of Polio Eradication, WHO’s Eastern Mediterranean Region.

*Summary of new polioviruses this week:*

- Afghanistan: two WPV1 cases and four WP1 positive environmental samples
- Pakistan: one WPV1 positive environmental sample
- Algeria: three cVDPV2 positive environmental samples
- Central African Republic: two cVDPV2 cases
- DR Congo: one cVDPV1 case
- Madagascar: two cVDPV1 positive environmental samples
- Nigeria: two cVDPV2 cases and one cVDPV2 positive environmental sample

---

**Coronavirus [COVID-19]**

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

**WHO Weekly Epidemiological and Operational updates**

*Last update: 17 May 2023*

- **Confirmed cases** :: 766 440 796
- **Confirmed deaths** :: 6 932 591
- **Vaccine doses administered**: 13 350 702 229

**Weekly epidemiological update on COVID-19 - 18 May 2023**

**Overview**

Globally, nearly 2.6 million new cases and over 17 000 deaths were reported in the last 28 days (17 April to 14 May 2023), a decrease of 14% and 26%, respectively, compared to the previous 28 days (20 March to 16 April 2023). The situation is mixed at regional levels, with increases in reported cases
seen in the South-East Asia and Western Pacific regions and increases in deaths in South-East Asia. As of 14 May 2023, over 766 million confirmed cases and over 6.9 million deaths have been reported globally.

Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 14 May 2023**

---

**Our World in Data**

**Coronavirus (COVID-19) Vaccinations**  [Accessed 20 May 2023]

:: 70% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.38 billion doses have been administered globally, and 75,149 are now administered each day.
:: 29.9% of people in low-income countries have received at least one dose.

Last update: 14 hours ago.

---

**Fact Sheet: HHS Details $5 Billion ‘Project NextGen’ Initiative to Stay Ahead of COVID-19**

May 11, 2023 News Release

...An initial investment of $5 billion, collectively referred to as Project NextGen, will accelerate and streamline the rapid development of the next generation of vaccines and treatments through public-private collaborations.

Based at the U.S. Department of Health and Human Services (HHS) and led by the Administration for Strategic Preparedness and Response (ASPR’s) Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH’s) National Institute of Allergy and Infectious Diseases (NIAID), Project NextGen will coordinate across the federal government and the private sector to advance the pipeline of new, innovative vaccines and therapeutics into clinical trials and potential review by the U.S. Food and Drug Administration (FDA) for authorization or approval, and commercial availability for the American people.

The program will focus on several areas, including:
- **Mucosal vaccines** such as those delivered intranasally, which could have the potential to dramatically reduce infection and transmission, in addition to preventing serious illness and death.
- **Vaccines that provide broader protection against variants** of concern and a longer duration of protection.
- **Pan-Coronavirus vaccines** which would protect against several different coronaviruses.
- **New, and more durable monoclonal antibodies** that are resilient against new variants as they arise.
- Advancing new technologies that will improve access and enable **faster, cheaper, rapid, and more flexible production of vaccines and therapeutics**.

Announced on April 10, the program has already started the activities necessary to bring next generation vaccines and treatments to Americans, including but not limited to:
- Advanced development efforts at **BARDA to examine immune responses across vaccines**, including furthering our understanding of what correlates of immunity can predict the success of next-generation vaccines.
- **Leveraging NIAID clinical trial networks to evaluate multiple early candidate vaccines**.
- **Public-private partnerships** between BARDA and vaccine and therapeutic developers to de-risk product development.
- **BARDA's support of innovative manufacturing and platform approaches** that will improve yields and will accelerate the availability of vaccines and therapeutics.

Building on experiences from HHS’s COVID-19 response efforts over the past 3-plus years, the Biden-Harris Administration will continue to address the ongoing threat of COVID-19 and to protect us against future epidemics from this same family of viruses...

::::::

UN OCHA – Current Emergencies

**Current Corporate Emergencies**

**Afghanistan**

*Editor’s Note:*

We observe that OCHA has removed Afghanistan from its listing of "Current Emergencies." We did not identify any explanation for its removal.

**Northern Ethiopia**

*Ethiopia - Situation Report, 18 May 2023*

**Somalia**

No new digest content identified.

**Türkiye/Syria Earthquakes**

17 May 2023

*Today's top news: Myanmar, Ethiopia, Sudan, Syria and Türkiye*

**Ukraine**

*Last Updated: 10 Feb 2023*
WHO & Regional Offices  [to 20 May 2023]
https://www.who.int/news
Selected News/Announcements/Statements
20 May 2023  News release
**WHO launches global network to detect and prevent infectious disease threats**

19 May 2023  News release
**Seventy-sixth World Health Assembly to focus on “saving lives, driving health for all” as WHO turns 75**

19 May 2023  News release
**Urgent action needed to tackle stalled progress on health-related Sustainable Development Goals**

18 May 2023  Statement
**Statement on the antigen composition of COVID-19 vaccines**

17 May 2023  Departmental news
**High-level resource mobilization conference to eliminate viral hepatitis**

17 May 2023  Departmental news
**Registration Open: Please apply to join the second UN High-Level Meeting on TB**

16 May 2023  News release
**WHO congratulates Benin and Mali for eliminating trachoma as a public health problem**

16 May 2023  Departmental news
**WHO calls for safe and ethical AI for health**

16 May 2023  Departmental news
**Scientists in Tahiti prepare to release sterilized mosquitoes to control dengue**

15 May 2023  Departmental news
**New WHO report highlights progress, but also remaining gaps, in ensuring a robust pipeline of antibiotic treatments to combat antimicrobial resistance (AMR)**

15 May 2023  Departmental news
**TDR and WHO announce TDA4Child, an operational research package to generate data on treatment decision algorithms for pulmonary tuberculosis in children**

WHO Regional Offices
Selected Press Releases, Announcements
**WHO African Region**
No new digest content identified.

**WHO Region of the Americas** PAHO
No new digest content identified.

**WHO South-East Asia Region** SEARO
No new digest content identified.

**WHO European Region** EURO
:: 17 May 2023   Media release
An mpox resurgence in the European Region this spring and summer? To prevent that, key measures must continue
:: 17 May 2023   News release
Cautiously celebrating our success in combatting mpox: new and updated resources offer inspiration and guidance on eliminating the disease

**WHO Western Pacific Region**
No new digest content identified.

::::::

**Disease Outbreak News (DONs)**
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

17 May 2023 | Myocarditis - United Kingdom of Great Britain and Northern Ireland

::::::

**New WHO Publications**
https://www.who.int/publications/i
Selected
19 May 2023
World health statistics 2023: monitoring health for the SDGs, sustainable development goals

18 May 2023
Foundations of medical oxygen systems: web annex A: technical considerations for the procurement of oxygen...

18 May 2023
Access to essential medicines: Medicines price information exchange

17 May 2023
Use of behavioural science in organizations a workforce survey. A tool for behavioural insights

17 May 2023
USA – HHS, FDA, CDC

HHS
News
Fact Sheet: HHS Provides Resources on Ways Communities Can Stay Protected from Mpox in Advance of Summer Months:
May 18, 2023 News Release

Statement from HHS Secretary Xavier Becerra on President Biden’s Intention to Nominate Dr. Monica Bertagnolli for Director of the National Institutes of Health
May 15, 2023 News Release

Fact Sheet: HHS Details $5 Billion ‘Project NextGen’ Initiative to Stay Ahead of COVID-19
May 11, 2023 News Release

FDA
Press Announcements
No new digest content identified.

FDA VRBPAC
Advisory Committee Calendar
Vaccines and Related Biological Products Advisory Committee May 18, 2023 Meeting Announcement - 05/18/2023
:: Vaccines and Related Biological Products Advisory Committee May 18, 2023 Meeting Briefing Document- FDA

CDC/ACIP [U.S.] [to 20 May 2023]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
New Funding Opportunity to Strengthen Outbreak Response through Data, Forecasting, and Analytics
May 19, 2023
The Centers for Disease Control and Prevention (CDC) launched a new Notice of Funding Opportunity (NOFO) through the Center for Forecasting and Outbreak Analytics (CFA) to establish an outbreak response network for disease forecasting...
ACIP Meetings
Next ACIP Meeting: June 21-22
Agenda: June 21-23, 2023 [3 pages]

MMWR Weekly
https://www.cdc.gov/mmwr/index2023.html
May 19, 2023 / No.20
PDF of this issue
- The CDC Domestic Mpox Response — United States, 2022–2023
- Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
- Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection — New York, 2022

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries [Selected]
No new content published since 5/11/23.

Europe

European Medicines Agency [EMA]
News & Press Releases
Guidance for industry to prevent and mitigate medicine shortages
News 17/05/2023
EMA has published recommendations for industry on good practices to ensure continuity in the supply of human medicines, prevent shortages and reduce their impact.

Medicine shortages are a global health problem and are increasingly affecting European countries. Shortages can lead to medicine rationing and delay in critical treatments, with a significant impact on patient care. In addition, patients may need to use less effective alternatives and face an increased risk of medication errors. Ensuring the availability of authorised medicines in the European Union (EU) is a key priority for EMA and the European medicines regulatory network.

The guidance describes the various stakeholders involved in the medicine supply chain and their responsibilities and role in the prevention and management of medicine shortages. It provides ten recommendations for marketing authorisation holders, wholesalers, distributors and manufacturers to minimise the occurrence of medicine shortages and their impact. The recommendations include:
- informing national competent authorities of potential or actual shortages as early as possible and providing detailed information to better predict the possible impact and implement preventive measures;
- establishing robust shortage prevention and shortage management plans;
- optimising pharmaceutical quality systems and increasing resilience of complex, multinational supply chains;
- timely communication between the various stakeholders in the medicine supply chain;
- general principles to promote fair and equitable distribution of medicines to meet the needs of patients.

The recommendations are based on the analysis of causes of shortages and regulators’ first-hand experience in coordinating the management of shortages, and industry associations have been consulted.

The guidance has been developed by the HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use, a joint working group established by EMA and the Heads of Medicines Agencies (HMA) focusing on the availability of authorised medicines, and was presented at a multi-stakeholder workshop on shortages held on 1 and 2 March 2023. It complements the guidance for patients’ and healthcare professionals’ organisations published last year to help prevent and manage shortages of human medicines.

::::

**European Centre for Disease Prevention and Control**
https://www.ecdc.europa.eu/en
News/Updates/Reports [Selected]
No new digest content identified.

::::

**Africa CDC**  [to 20 May 2023]
http://www.africacdc.org/
News
News / Stories
Africa CDC Digital Transformation Strategy to revolutionize and strengthen Public Health systems across the continent
18 May 2023

Press Releases
Joint Regional Technical Meeting on Mortality Surveillance in Africa
17 May 2023

Press Releases
The signing of a New Agreement to Drive Vaccine Impact in Africa
15 May 2023
[See Milestones/Perspectives above for detail]

::::

**China CDC**
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China  [to 20 May 2023]
Large-scale COVID reemergence 'unlikely' despite uptick in cases
2023-05-19
The risk of a new large-scale COVID-19 outbreak in China in the short term is minimal, despite a recent uptick in new infections, according to health experts.

China sees low possibility of large-scale COVID-19 epidemic outbreak: health expert
2023-05-18
China sees low possibility of a large-scale COVID-19 epidemic outbreak in the country at the current stage, according to an expert with the Chinese Center for Disease Control and Prevention (China CDC).

Expert: COVID-19 widespread, vaccines needed fast
2023-05-17
A prominent Chinese respiratory disease expert, Zhong Nanshan, said at a medical symposium on Monday that between 20 and 25 percent of fever patients treated in clinics in Guangzhou, Guangdong province, were actually infected with some variant of COVID-19.
Bill & Melinda Gates Medical Research Institute  [to 20 May 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people

News: Articles and Publications
No new digest content identified.

CARB-X  [to 20 May 2023]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 20 May 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Publications-Digests/Statements
:: Vaccines and Global Health: The Week in Review -Current edition
:: Informed Consent: A Monthly Review – May 2023
:: Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest – May 2023
:: Public Consultations Watch :: Global Calls for Input/Public Comment/ -
   03 May 2023 – Issue 03

CEPI – Coalition for Epidemic Preparedness Innovations  [to 20 May 2023]
http://cepi.net/
Latest News
Re-engineering for equity: CEPI’s vision for achieving equitable access to countermeasures for epidemic and pandemic threats
Dr Richard Hatchett discusses CEPI’s approach to equity alongside a description of CEPI’s Equitable Access Framework
News  19 May 2023

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 20 May 2023]
https://cioms.ch/
News; Publications; Events
CIOMS Cumulative Glossary, with a focus on Pharmacovigilance (Version 2.1)
The CIOMS Cumulative Glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance. It includes links to the reports and, where applicable, provides references to the sources from which the definitions were adopted or modified. Version 2.1 covers the terms included in thirteen different CIOMS reports published between 1992 and 2022. It does not cover CIOMS reports on the subjects of ethics, clinical pharma...
Year of publication: 2023  Number of pages: 144  SKU: 7912
Experiences, Enablers, and Challenges in Service Delivery and Integration of COVID-19 Vaccines: a Rapid Systematic Review

Abstract: The COVID-19 vaccination is a crucial public health intervention for controlling the spread and severity of the SARS-CoV2 virus. COVID-19 vaccines have been developed in record time, but their deployment has varied across countries, owing to differences in health systems.

Melissa Slogan May 11, 2023
Fondation Merieux [to 20 May 2023]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 20 May 2023]
https://www.gavi.org/
News Releases
16 May 2023
Advocating for greater visibility for global health priorities: Gavi and Virchow Foundation join forces
Raise awareness for and increase visibility of global health. Gavi and the Virchow Foundation will work together to raise awareness on global and public health issues and push for greater equity in health coverage around the world.
[The Virchow Foundation for Global Health was established in 2021 with the support of the German National Academy of Sciences Leopoldina, the Berlin-Brandenburg Academy of Sciences and Humanities as well as Members of the German Parliament to contribute to the improvement of health worldwide.]

15 May 2023
Amidst crises, Malawi showcases resilience with major vaccination push
- Malawi becomes the third African country to introduce typhoid conjugate vaccine (TCV) into routine immunisation as Ministry of Health and partners collaborate to protect children across the country from typhoid fever.
- Prior to TCV introduction, Malawi will undertake an ambitious one week push to reach more than 9 million children – nearly half the country’s population – with an integrated “catch-up” campaign providing vaccines against typhoid fever, measles, rubella, and polio, as well as a vitamin A supplement.
- This large scale effort comes at a critical time as Malawi battles multiple crises, with Cyclone Freddy leaving more than half a million people displaced and increasing the risk of vaccine-preventable outbreaks.

15 May 2023
Signing of a new agreement to drive vaccine impact in Africa

GHIT Fund [to 20 May 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
May 16, 2023
“Nagasaki Outcome Statement” to accelerate progress on neglected tropical diseases (NTDs) for G7 Health Ministers. “Accelerating Research and Development, and Access and Delivery for NTDs”

Global Fund [to 20 May 2023]
The Global Fund Commits Nearly US$1 Million in Emergency Funding to Help Avoid Malaria Surge in Mozambique

The Global Fund to Fight AIDS, Tuberculosis and Malaria has committed nearly US$1 million in emergency funding to Mozambique to mitigate the impact of the floods and Cyclone Freddy on malaria programs in the southern provinces of the country.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 20 May 2023]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories  [to 20 May 2023]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute  [to 20 May 2023]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project  [to 20 May 2023]
http://www.humanvaccinesproject.org/
News
Making Headlines  May 15, 2023
The groundbreaking plan to map the entire human immune system
The Human Immunome Project is one of the most ambitious projects in biology, and it could transform human health.

IAVI  [to 20 May 2023]
https://www.iavi.org/
Latest News
May 17, 2023
Zendal and IAVI announce expanded agreement to partner on development of TB vaccine candidate MTBVAC
- TB kills 1.6 million people a year, causing more deaths than any other single infectious disease apart from COVID-19, and sickens more than 10 million people annually.
- A new TB vaccine is needed to reach global END TB goals.
MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.

**INSEMER** [to 20 May 2023]
https://www.inserm.fr/en/home/
*Press Releases*
No new digest content identified.

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
*Selected Statements, Press Releases, Research*
No new digest content identified.

**ICRC** [to 20 May 2023]
*What’s New [Selected]*
**Red Cross report: Climate change, environmental degradation and protracted armed conflict are exacerbating humanitarian needs across the Near and Middle East**
High temperatures and scarce fresh water supply, drought, and intense rainfall are increasingly common across the region. Protracted conflicts undermine institutional capacity in environmental governance and have taken a toll on natural resources.
18-05-2023 | News release

**IFFIm**
http://www.iffim.org/
*Press Releases/Announcements*
No new digest content identified.

**IFRC** [to 20 May 2023]
*Press Releases [Selected]*
Press release 16/05/2023
**Cyclone Mocha: Access and time of the essence to help affected families in Bangladesh and Myanmar**
Press release 16/05/2023
**New shipment of IFRC humanitarian aid arrives in Port Sudan amid conflict**

**Institut Pasteur** [to 20 May 2023]
*Press Documents*
No new digest content identified.
ISC / International Science Council  [to 20 May 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
No new digest content identified.

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC  [to 20 May 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
Crying out for action: Protect children from pneumonia in Africa’s most fragile countries
By Dr. Anita Shet and Dr. Dickson Awah
Originally posted on reliefweb.int

IVI  [to 20 May 2023]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security  [to 20 May 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News [Selected]
No new digest content identified.

MSF/Médecins Sans Frontières  [to 20 May 2023]
http://www.msf.org/
Latest [Selected Announcements]
Global health
G7 countries must commit to safeguarding humanitarian assistance
Statement 19 May 2023

Lebanon
Syrians in Lebanon avoid healthcare in fear of deportations
Project Update 17 May 2023
National Academy of Medicine - USA [to 20 May 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 20 May 2023]
https://www.nationalacademies.org/newsroom?
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 20 May 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee (NVAC)
June 15-16, 2023 NVAC Meeting

NIH [to 20 May 2023]
http://www.nih.gov/
News Releases
Clinical trial of mRNA universal influenza vaccine candidate begins
May 15, 2023 — Trial will test the experimental vaccine for safety and its ability to induce an immune response.

PATH [to 20 May 2023]
https://www.path.org/media-center/
Press Releases
PATH joins call for stronger primary health care and self-care
May 18, 2023
PATH, as part of the Global Self-Care Federation, joins a global call to reorient health systems to primary health care and self-care as a resilient foundation for universal health coverage.

Rockefeller Foundation [to 20 May 2023]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Press Release
Think7 and Think20 Leaders Launch a Shared Agenda For Global Cooperation
05.15.23

Sabin Vaccine Institute [to 20 May 2023]
UNAIDS [to 20 May 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
19 May 2023
Brazil announces its commitment to the global initiative against HIV-related stigma and discrimination

18 May 2023
Virtual course on HIV, gender and human rights: empowering medical teachers in Guatemala

17 May 2023
A rainbow of hope for LGBTQI+ people in rural Japan

UNICEF [to 20 May 2023]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements
Press release 19 May 2023
Over half a million children at risk of malnutrition in Malawi
Lilongwe, 19 May 2023 – At least 573,000 children under five are at risk of suffering from malnutrition in Malawi, UNICEF warns. Despite recent progress in reducing chronic malnutrition, acute food insecurity—compounded by recurrent climate shocks, preventable disease outbreaks, economic instability, and chronic underfunding in the social sectors...

Remarks 18 May 2023
Afghanistan - A Children’s Crisis: UNICEF Afghanistan Representative Fran Equiza’s remarks at the Daily Press Briefing by the Office of the Spokesperson for the Secretary-General
NEW YORK, 18 May 2023 - "A few weeks ago, I visited a health clinic outside Kabul, replete with female health workers, and lines of mothers waiting patiently for nurses to vaccinate their babies. One mother trusted me to give polio drops to her baby girl. And when the nurse confirmed that her baby was now safe from polio, she smiled. "I don’t..."

Press release 18 May 2023
UNICEF calls for urgent action to respond to alarming levels of increasing sexual violence against girls and women in eastern DRC
KINSHASA, 18 May 2023 – UNICEF is calling for an urgent and significant scale-up of interventions and funding to respond to the escalating number of cases of sexual violence reported against children and women in North Kivu province in the eastern Democratic Republic of the Congo (DRC). Reports of gender-based violence (GBV) against girls and... 

Press release 17 May 2023
100 days after earthquakes hit Türkiye and Syria, millions of children continue to face desperate conditions

NEW YORK/AMMAN/ANKARA/DAMASCUS/GENEVA, 17 May 2023 – One hundred days after the deadliest earthquakes in Türkiye and Syria's recent history, millions of children and families are struggling to rebuild their lives, with 2.5 million children in Türkiye and 3.7 million in Syria in need of continued humanitarian assistance. The two initial devastating...

Press release 16 May 2023
Millions of children at risk in Myanmar and Bangladesh in the aftermath of Cyclone Mocha

NEW YORK/BANGKOK/NEPAL, 16 May 2023 – The trail of destruction left by Cyclone Mocha – which tore through parts of Bangladesh and Myanmar on Sunday – is causing severe disruption to the lives of millions of vulnerable children and families, including many already

Unitaid [to 20 May 2023]
https://unitaid.org/
Featured News
19 May 2023
Unitaid-WHO partnership has advanced over 60 updates to global health policy, leading to unprecedented scale-up of game-changing health solutions

19 May 2023
Unitaid announces new estimates projecting more effective and affordable HIV treatments to generate more than US$7 billion in savings by 2030

Vaccine Equity Cooperative [nee Initiative] [to 20 May 2023]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 20 May 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.
**Vaccine Confidence Project** [to 20 May 2023]  
http://www.vaccineconfidence.org/  
*News, Research and Reports*  
*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 20 May 2023]  
http://www.chop.edu/centers-programs/vaccine-education-center  
*No new digest content identified.*

**Wellcome Trust** [to 20 May 2023]  
https://wellcome.ac.uk/news  
*News. Opinion, Reports*  
*Research story*  
**Could new biomaterials transform how we understand and treat diseases?**  
*Author Dr Chris Spicer 18 May 2023*

**The Wistar Institute** [to 20 May 2023]  
*Press Releases*  
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 20 May 2023]  
https://www.wfpha.org/  
*Latest News - Blog*  
*No new digest content identified.*

**World Medical Association [WMA]** [to 20 May 2023]  
*Press Releases*  
**Global Violence Against Physicians Condemned by WMA President**  
*16.05.2023*

**World Organisation for Animal Health (OIE)** [to 20 May 2023]  
https://www.oie.int/en/  
*Press Releases, Statements*  
*News*  
**WOAH to hold its 90th General Session the 21-25 May**  
*Published on 11 May 2023*

::::::

**ARM [Alliance for Regenerative Medicine]** [to 20 May 2023]
BIO [to 20 May 2023]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 20 May 2023]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 20 May 2023]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 20 May 2023]
https://ifpma.org/
Selected Press Releases, Statements, Publications
Position paper 15 May 2023
IFPMA Note for Guidance on sponsorship of events and meetings (2023 update)
Collaborations between healthcare professionals (HCPs) and the pharmaceutical industry are essential and ensure that patients have access to the medicines they need and that healthcare professionals have up-to-date comprehensive information about the diseases they treat and the medicines they prescribe.

International Alliance of Patients’ Organizations – IAPO [to 20 May 2023]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest announcements identified

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
IGBA detailed comments and proposals on the Pandemic Accord (Zero Draft - May 2023) [11 May 2023]

PhRMA [to 20 May 2023]
Press Releases
No new digest announcements identified

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases - No new digest announcements identified

Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News
IV International Symposium Cancer 2023
Varadero, Cuba, September, 2023

Cinagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News
May 19, 2023
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

Gamaleya National Center
Latest News and Events - See Russia above.
GSK
*Press releases for media* - No new digest announcements identified

IMBCAMS, China
*Home* - Website not responding at inquiry

Janssen/JNJ
*Press Releases* - No new digest announcements identified

Merck
*News releases* - No new digest announcements identified

Moderna
*Press Releases*
19 May, 2023
**Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting**

Nanogen
*News* - No new digest announcements identified

Novartis
*News* - No new digest announcements identified

Novavax
*Press Releases* - No new digest announcements identified

Pfizer
*Recent Press Releases*
**FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization**
05.18.2023
- The positive vote is based on compelling scientific evidence presented, including Phase 3 efficacy and safety data in pregnant individuals and their infants
- FDA decision expected in August 2023
- If authorized, the vaccine candidate would help protect infants at first breath through six months of life against RSV disease and its potential complications

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur - No new digest announcements identified
*Press Releases*

Serum Institute of India
*NEWS & ANNOUNCEMENTS* - No new digest announcements identified
Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases - No new digest announcements identified

SK Biosciences
Press Releases
SK bioscience Announces Contract Manufacturing Agreement with MSD for Next-Generation Zaire Ebola Vaccine Candidate
The vaccine will be manufactured at L HOUSE, SK bioscience’s vaccine manufacturing plant.
2023.05.08

Takeda
Newsroom - No new digest announcements identified

Valneva
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media
The First of Its Kind in the World! The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma has been Approved for Clinical Trials by The National Medical Products Administration of China
2023-05-17

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

Contents [click to move among sections]
:: Coronavirus [COVID-19]
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

**AJOB Empirical Bioethics**
Volume 14, 2023  Issue 2
https://www.tandfonline.com/toc/uabr21/current
Article
[Reviewed earlier]

**AMA Journal of Ethics**
Volume 25, Number 5: E305-379   May 2023
https://journalofethics.ama-assn.org/issue/ipe-and-innovation

**IPE and Innovation**
Interprofessional education (IPE) began as a health and social care movement in the early 1970s and took firm hold in US-based accreditation standards in the mid-2000s. IPE should start early in health professions education and prepare clinicians for cross-disciplinary work culture that nourishes quality, collegiality, and safety in a rapidly evolving health sector. Since formation of the Interprofessional Education Collaborative®, IPE trends have gained momentum. This theme issue considers strategies for wider implementation of educational innovations that promote patient-centered and collaborative care, reduce iatrogenic harm, and improve health outcomes.

**American Journal of Infection Control**
May 2023  Volume 51  Issue 5  p481-602
http://www.ajicjournal.org/current
[Reviewed earlier]

**American Journal of Preventive Medicine**
May 2023  Volume 64  Issue 5  p611-780
http://www.ajicjournal.org/current
[Reviewed earlier]

**American Journal of Public Health**
May 2023  113(5)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]
Population Genomic Screening for Three Common Hereditary Conditions A Cost-Effectiveness Analysis
Gregory F. Guzauskas, MSPH, PhD, Shawn Garbett, MS, Zilu Zhou, MPH, Jonathan S. Schilcrudt, PhD, ... et al. Pages:585–595

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 FREE
Teresa H. Evering, MD, MS, Kara W. Chew, MD, MS, Mark J. Giganti, PhD, Carlee Moser, PhD, ... et al. Pages:658–666

Research and Reporting Methods Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data FREE
William J. Hulme, PhD, Elizabeth Williamson, PhD, Elsie M.F. Horne, PhD, Amelia Green, PhD, ... et al. Pages:685–693

What are economic costs and when should they be used in health economic studies? Authors: Hugo C. Turner, Frank G. Sandmann, Laura E. Downey, Stacey Orangi, Yot Teerawattananon, Anna Vassall and Mark Jit
Content type: Review 15 May 2023

What are economic costs and when should they be used in health economic studies? Authors: Hugo C. Turner, Frank G. Sandmann, Laura E. Downey, Stacey Orangi, Yot Teerawattananon, Anna Vassall and Mark Jit
Content type: Review 15 May 2023
The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods study

COVID-19 pandemic posed a major impact on the availability and affordability of essential medicines. This study aimed to assess the knock-on effects of the COVID-19 pandemic on the supply availability of non-c...

Authors: Zeleke Mekonnen, Tsegaye Melaku, Gudina Terefe Tucho, Mohammed Mecha, Christine Årdal and Marianne Jahre

Citation: BMC Health Services Research 2023 23:513

New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants

Authors: Padmini Srikantiah and Keith P. Klugman

Citation: BMC Medicine 2023 21:177

Abstract

As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving.
Exploring the factors contributing to low vaccination uptake for nationally recommended routine childhood and adolescent vaccines in Kenya

Vaccination remains the most effective means of reducing the burden of infectious disease among children. It is estimated to prevent between two to three million child deaths annually. However, despite being a...

Authors: Tene-Alima Essoh, Gbadebo Collins Adeyanju, Abdu A. Adamu, Haoua Tall, Aristide Aplogan and Collins Tabu
Citation: BMC Public Health 2023 23:912
Content type: Research Published on: 19 May 2023

COVID-19 pandemic policing and public (non)compliant behaviour: dataset from Nigeria

The unprecedented nature of COVID-19 pandemic lockdown order projected to contain the pandemic and the global use of the police to enforce the order has necessitated the investigation of public (non-compliant) behavior and police intervention (misconduct). Given that the phases of easing the lockdown and reopening of the economy were already underway in Nigeria in September 2020, four months post-lockdown, this period was deemed suitable to collect the data.

Authors: Aliu Oladimeji Shodunke, Sodiq Abiodun Oladipupo, Sheriffdeen Olasunkanmi Adeoti, Abdulgafar Abidemi Oloredde, Adebusayo Joel Alowolodu, Oriyomi Oluwasegun Seriki, Ayobami Habeeb Akindele, Isiaka Adam Folorusnho, Glory David Adebayo and Onyinye Faith Mbanefo
Citation: BMC Research Notes 2023 16:79
Content type: Data Note Published on: 15 May 2023

BMJ Evidence-Based Medicine
April 2023 - Volume 28 - 2
https://ebm.bmj.com/content/28/2
[Reviewed earlier]

BMJ Open
May 2023 - Volume 13 - 5
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]
May 2023
https://thebulletin.org/magazine/2023-05/
[New issue; No digest content identified]

**Bulletin of the World Health Organization**
Volume 101(5); 2023 May 1
https://www.ncbi.nlm.nih.gov/pmc/issues/434533/
[Reviewed earlier]

**Cell**
May 11, 2023 Volume 18 Issue 10 p2041-2282
https://www.cell.com/cell/current
[New issue; No digest content identified]

**Child Care, Health and Development**
Volume 49, Issue 3 Pages: 407-616 May 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**
Volume 113, Issue 5 Pages: 935-1161 May 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

**Clinical Therapeutics**
April 2023 Volume 45 Issue 4 p303-386
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

**Clinical Trials**
Volume 20 Issue 2, April 2023
https://journals.sagepub.com/toc/ctja/20/2
[Reviewed earlier]

**Conflict and Health**
http://www.conflictandhealth.com/
[Accessed 20 May 2023]
The first year of the COVID-19 pandemic in humanitarian settings: epidemiology, health service utilization, and health care seeking behavior in Bangui and surrounding areas, Central African Republic
Despite increasing evidence on COVID-19, few studies have been conducted in humanitarian settings and none have investigated the direct and indirect effects of the pandemic in the Central African Republic. We studied the COVID-19 epidemiology, health service utilization, and health care seeking behavior in the first year of the pandemic in Bangui and surrounding areas.

Authors: Chiara Altare, Natalya Kostandova, Gbètoho Fortuné Gankpe, Patricia Nalimo, Abdoul Azizi Almoustapha Abaradine, Sophie Bruneau, Caroline Antoine and Paul B. Spiegel

Content type: Research 20 May 2023

Contemporary Clinical Trials
Volume 127  April 2023
[Reviewed earlier]

The CRISPR Journal
Volume 6, Issue 2 / April 2023
https://www.liebertpub.com/toc/crispr/6/2
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Medical Research and Opinion
Volume 39, Issue 5 2023
https://www.tandfonline.com/toc/icmo20/current
[Reviewed earlier]

Current Opinion in Infectious Diseases
June 2023 - Volume 36 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 23, Issue 1  Pages: 1-87  March 2023
https://onlinelibrary.wiley.com/toc/14718847/current
Development in Practice
Volume 33, Issue 3, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 3  May 2023
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 2  Pages: 245-542  April 2023
https://onlinelibrary.wiley.com/toc/14677717/2023/47/2
[Reviewed earlier]

EMBO Reports
Volume 24  Issue 5  4 May 2023
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 5—May 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 42  March 2023
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
Conflicts of interest :: Surrogate consent and decisional impairment

Ethics & Human Research
Volume 45, Issue 2  Pages: 1-42  March–April 2023
https://onlinelibrary.wiley.com/toc/25782363/current

Ethics & International Affairs
Volume 37 - Issue 1 - Spring 2023
https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue

Ethics, Medicine and Public Health
Volume 27  April 2023

The European Journal of Public Health
Volume 33, Issue 2, April 2023
https://academic.oup.com/eurpub/issue/33/2

Expert Review of Vaccines
Vol 22 (1) 2023 Issue In Progress
https://www.tandfonline.com/toc/ierv20/current

Foreign Affairs
May/June 2023  Volume 102, Number 3
https://www.foreignaffairs.com/issues/2023/102/3
[New issue; No digest content identified]

Forum for Development Studies
Volume 50, 2023 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[New issue; No digest content identified]
The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally...
colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

**Health Economics, Policy and Law**
Volume 18 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

**Health Policy and Planning**
Volume 38, Issue 4, May 2023
https://academic.oup.com/heapol/issue/38/4
[Reviewed earlier]

**Health Research Policy and Systems**
http://www.health-policy-systems.com/content
[Accessed 20 May 2023]
*A framework for seroepidemiologic investigations in future pandemics: insights from an evaluation of WHO’s Unity Studies initiative*

The WHO Unity Studies initiative supports countries, especially low- and middle-income countries (LMICs), in conducting seroepidemiologic studies for rapidly informing responses to the COVID-19 pandemic. Ten g...

Authors: Karen Hennessey, Lorenzo Pezzoli and Carsten Mantel
Citation: Health Research Policy and Systems 2023 21:34
Content type: Research Published on: 16 May 2023

**Human Gene Therapy**
Volume 34, Issue 7-8 / April 2023
https://www.liebertpub.com/toc/hum/34/7-8
[Reviewed earlier]

**Humanitarian Practice Network**
https://odihpn.org/
*Featured Publications*
[No new digest content identified]
Climate change and infectious disease: a review of evidence and research trends

Authors: Paige Van de Vuurst and Luis E. Escobar

Citation: Infectious Diseases of Poverty 2023 12:51

Content type: Scoping Review Published on: 16 May 2023

Abstract
Background
Climate change presents an imminent threat to almost all biological systems across the globe. In recent years there have been a series of studies showing how changes in climate can impact infectious disease transmission. Many of these publications focus on simulations based on in silico data, shadowing empirical research based on field and laboratory data. A synthesis work of empirical climate change and infectious disease research is still lacking.

Methods
We conducted a systemic review of research from 2015 to 2020 period on climate change and infectious diseases to identify major trends and current gaps of research. Literature was sourced from Web of Science and PubMed literary repositories using a key word search, and was reviewed using a delineated inclusion criteria by a team of reviewers.

Results
Our review revealed that both taxonomic and geographic biases are present in climate and infectious disease research, specifically with regard to types of disease transmission and localities studied. Empirical investigations on vector-borne diseases associated with mosquitoes comprised the majority of research on the climate change and infectious disease literature. Furthermore, demographic trends in the institutions and individuals published revealed research bias towards research conducted across temperate, high-income countries. We also identified key trends in funding sources for most recent literature and a discrepancy in the gender identities of publishing authors which may reflect current systemic inequities in the scientific field.
Conclusions
Future research lines on climate change and infectious diseases should consider diseases of direct transmission (non-vector-borne) and more research effort in the tropics. Inclusion of local research in low- and middle-income countries was generally neglected. Research on climate change and infectious disease has failed to be socially inclusive, geographically balanced, and broad in terms of the disease systems studied, limiting our capacities to better understand the actual effects of climate change on health.

International Health
Volume 15, Issue 3, May 2023
https://academic.oup.com/inthealth/issue/15/3
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol. 10 No. 5 (2023): May 2023
https://www.ijcmph.com/index.php/ijcmph/issue/view/100
Original Research Articles
Incidence and severity of COVID-19 infection among health care workers following vaccination: a cross sectional survey in Maharashtra
Aditya Kataria, Priyanka Kataria, Pradeep Suryawanshi
1726-1730
DOI: 10.18203/2394-6040.ijcmph20231041

International Journal of Epidemiology
Volume 52, Issue 2, April 2023
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 16 Issue 1 2023
https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/1
[Reviewed earlier]

JAMA
May 16, 2023, Vol 329, No. 19, Pages 1625-1710
https://jamanetwork.com/journals/jama/currentissue
Special Communication

**The Economic Burden of Racial, Ethnic, and Educational Health Inequities in the US**

Thomas A. LaVeist, PhD; Eliseo J. Pérez-Stable, MD; Patrick Richard, PhD, MA; et al.

This study estimates the economic burden of health inequities for racial and ethnic minority populations.

Editorial

**The US Health Equity Crisis—An Economic Case for a Moral Imperative?**

Rishi K. Wadhera, MD, MPP, MPhil; Issa J. Dahabreh, MD, ScD

Viewpoint

**The Politics of Informed Consent and the Limits of the First Amendment**

Nadia N. Sawicki, JD, MBioeth

Physicians are accustomed to disclosing the risks and benefits of treatment as part of their ethical and legal duty to secure informed consent. Generally, physicians have the freedom to decide how to communicate this information, and to tailor their disclosures to the needs of individual patients. However, in today’s highly politicized climate, some state legislatures are eliminating this opportunity for professional discretion. Physicians are increasingly being compelled to communicate state-mandated messaging that may be at odds with their professional judgment, violating their ethical duty to secure informed consent by “present[ing] relevant information accurately and sensitively, in keeping with the patient’s preferences for receiving medical information.”

Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination

Samuel So, MBBS; Norah Terrault, MD, MPH; Erin E. Conners, PhD, MPH

This Viewpoint describes new recommendations from the CDC regarding universal screening of adults for hepatitis B virus infection.

JAMA Health Forum

May 2023, Vol 4, No. 5
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics

May 2023, Vol 177, No. 5, Pages 445-547
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis

May 2023 - Volume 21 - Issue 5
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
Evidence Syntheses
Identifying H1N1 and COVID-19 vaccine hesitancy or refusal among health care providers: a scoping review
Gallant, Allyson J.; Harding, Andrew; Johnson, Catie; More

Journal of Adolescent Health
May 2023 Volume 72 Issue 5 p647-826
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 77 (2023)
https://www.jair.org/index.php/jair
Contents
[New issue; No digest content identified]

Journal of Community Health
Volume 48, issue 2, April 2023
[Reviewed earlier]

Journal of Current Medical Research and Opinion
...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
May 5, 2023 Vol 6, No 05 (2023)
https://www.cmro.in/index.php/jcmro/issue/view/67
[New issue; No digest content identified]

Journal of Development Economics
Volume 162 May 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 18 Issue 1-2, February-April 2023
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
April 2023 - Volume 77 - 4
Journal of Evidence-Based Medicine  
Volume 16, Issue 1  Pages: 1-100  March 2023  
https://onlinelibrary.wiley.com/toc/17565391/current  
[Reviewed earlier]

Journal of Global Ethics  
Volume 19, Issue 1 (2023)  
http://www.tandfonline.com/toc/rjge20/current  
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)  
Volume 34, Number 2, May 2023  
https://muse.jhu.edu/issue/50186  
Table of Contents  
[Reviewed earlier]

Journal of Immigrant and Minority Health  
Volume 25, issue 2, April 2023  
Contents  
[Reviewed earlier]

Journal of Immigrant & Refugee Studies  
Volume 21, 2023  Issue 2  
https://www.tandfonline.com/toc/wimm20/current  
[Reviewed earlier]

Journal of Infectious Diseases  
Volume 227, Issue 7, 1 April 2023  
https://academic.oup.com/jid/issue/227/7  
[Reviewed earlier]

Journal of International Development  
Volume 35, Issue 3  Pages: 383-535  April 2023  
https://onlinelibrary.wiley.com/toc/10991328/current  
Special Issue: Brokering Development  
[Reviewed earlier]
Research

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case

Monica Hildegard Otto, Patrizio Armeni, Francesco Costa, Francesco Malandrini and Claudio Jommi

Citation: Journal of Pharmaceutical Policy and Practice 2023 16:67

Content type: Research Published on: 17 May 2023

Abstract

Early access programs (EAPs) generally refer to patient access to medicines/indications before marketing authorization, possibly extended to price and reimbursement approval. These programs include compassionate use, which is usually covered by pharmaceutical companies, and EAPs reimbursed by third-party payers. This paper aims at comparing EAPs in four European countries (France, Italy, Spain, UK) and providing empirical evidence on EAPs in Italy. The comparative analysis was conducted through a literature review (including scientific and grey literature), complemented by 30-min semi-structured interviews with local experts. The Italian empirical analysis employed data available on the National Medicines Agency website. Although EAPs are very different across countries, they exhibit some common features: (i) eligibility criteria refer to the absence of valid therapeutic alternatives and a presumed favourable risk–benefit profile; (ii) payers do not allocate a pre-determined budget to these programs; (iii) total spending on EAPs is unknown. The French EAPs seem to be the most structured, financed through social insurance, covering pre-marketing, post-marketing and pre-reimbursement phases and providing for data collection. Italy's approach to EAPs has been varied, with several programs covered by different payers, including the cohort-based 648 List (for both early access and off-label use), the nominal-based 5% Fund, and Compassionate Use. Most applications to EAPs are from the Antineoplastic and immunomodulating drug class (ATC L). Some 62% of indications in the 648 List are either not under clinical development or have never been approved (pure off-label use). For those subsequently approved, most approved indications coincide with those covered through EAPs. Only the 5% Fund provides data on economic impact (€ 81.2 million in 2021;
average cost per patient € 61.5K). Diverse EAPs are a possible source of inequalities in access to medicines across Europe. A harmonization of these programs, though difficult to achieve, could be modelled on the French EAPs and provide key advantages, not least of which a common effort to collect real-world data in parallel with clinical trials and clear separation between EAPs and off-label use programs.

Journal of Public Health Management & Practice
May/June 2023 - Volume 29 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 44, issue 1, March 2023
https://link.springer.com/journal/41271/volumes-and-issues/44-1
Articles
[Reviewed earlier]

Journal of the Royal Society – Interface
May 2023 Volume 20 Issue 202
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 30, Issue 3, April 2023
https://academic.oup.com/jtm/issue
[New issue; No digest content identified]

Journal of Virology
Volume 97 Number 4 April 2023
http://jvi.asm.org/content/current
Virology Editorial 28 March 2023
A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses
James C. Alwine, et al.
https://doi.org/10.1128/jvi.00365-23
When humans experience a new, devastating viral infection such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), significant challenges arise. How should individuals as well as societies respond to the situation? One of the primary ...

The Lancet
May 20, 2023 Volume 401 Number 10389 p1629-1744
https://www.thelancet.com/journals/lancet/issue/current
Comment
Offline: The case for global health
Richard Horton

Global health has become fashionably unfashionable. The case against global health is strong. Global health is the invention of a largely white and wealthy elite residing in high-income, English-language speaking countries. The discipline claims to be concerned about the health of people living in low-income and middle-income settings. But the resources—human, infrastructural, and financial—underpinning global health are mostly concentrated in those countries already replete with power and money. “Helicopter” research is not uncommon. The contribution of scientists and research funders to sustainable advances in health care in the countries of their alleged concern is minimal. More often, the relationship between western medical science and the countries they work in is extractive. Global health institutions are mostly led by western-educated men. Global health agencies are only superficially member-state organisations. In truth, influence lies with those nations providing the greatest resources. Global health has enabled public health schools and university departments to continue to enrich themselves through exorbitant student fees and generous research grants. Global health journals are no better. Most are creatures of western medical publishing houses, even those that proclaim radical open access histories. The unearned privileges of a few suppress the justified demands of the many. It is hard to avoid the conclusion that global health is little more than an exclusive club, disguising its colonial origins and practices in the stirring language of equity and justice...

...While we identify enemies among ourselves, we miss the larger story of just who our opponents really are—those trying to destroy the conditions for achieving the right to health, equity, liberty, and social justice. For the real enemies of the values we stand for do not sit within the ranks of global health. They are to be found in governments that instinctively mistrust—and who wish to undermine and defund—global organisations. They will be found among those who demonise refugees. They are the climate sceptics, anti-vaxxers, and purveyors of scientific misinformation. They are those who attack the redistribution of wealth, those who believe that war brings peace, and those who defend racism under the guise of patriotism. Global health practitioners should certainly engage in robust discussions about the meaning of their discipline. But they should be clear about who our struggle is really against. It is not global health. Instead, we must work harder together to create a new political frontier and forge a new collective against the true enemies of health.

Articles

Effectiveness of handwashing with soap for preventing acute respiratory infections in low-income and middle-income countries: a systematic review and meta-analysis
Ian Ross, et al.
Open Access

The Lancet Child & Adolescent Health
May 2023 Volume 7 Number 5 p297-366, e11
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]
Lancet Global Health
May 2023 Volume 11 Number 5 e629-e795
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Apr 2023 Volume 23 Number 4 p381-508, e121-e165
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
May 2023 Volume 8 Number 5 e318-e390
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
May 2023 Volume 11 Number 5 p391-492, e41-e49
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 27, issue 5, May 2023
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 43 Issue 4, May 2023
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 101, Issue S1 Pages: 1-892 April 2023
https://onlinelibrary.wiley.com/toc/14680009/current
Special Centennial Issue: The Future of Population Health: Challenges & Opportunities
[Reviewed earlier]

Nature
Volume 617 Issue 7961, 18 May 2023
https://www.nature.com/nature/volumes/617/issues/7961
Editorial  16 May 2023

**Research assessment exercises are necessary — but we need to learn to do them better**

Australia is overhauling its research evaluation system — an opportunity for it, and other countries, to review what makes a system work for everyone.

Comment  17 May 2023

**Create an IPCC-like body to harness benefits and combat harms of digital tech**

Emerging information technologies, including ChatGPT, require proper stewardship. An intergovernmental panel to synthesize the evidence offers the best path forward.

Joseph Bak-Coleman, Carl T. Bergstrom, Timmons Roberts

**Nature Biotechnology**

Volume 41 Issue 4, April 2023
https://www.nature.com/nbt/volumes/41/issues/4
[Reviewed earlier]

**Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 20 May 2023)
[No new digest content identified]

**Nature Genetics**

Volume 55 Issue 5, May 2023
https://www.nature.com/ng/volumes/55/issues/5
[Reviewed earlier]

**Nature Human Behaviour**

Volume 7 Issue 4, April 2023
https://www.nature.com/nathumbehav/volumes/7/issues/4
[Reviewed earlier]

**Nature Medicine**

Volume 29 Issue 4, April 2023
https://www.nature.com/nm/volumes/29/issues/4
[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 22 Issue 5, May 2023
https://www.nature.com/nrd/volumes/22/issues/5
[Reviewed earlier]
**Nature Reviews Genetics**  
Volume 24 Issue 5, May 2023  
https://www.nature.com/nrg/volumes/24/issues/5  
[Reviewed earlier]

**Nature Reviews Immunology**  
Volume 23 Issue 4, April 2023  
https://www.nature.com/nri/volumes/23/issues/4  
[Reviewed earlier]

**New England Journal of Medicine**  
May 18, 2023  Vol. 388 No. 20  
https://www.nejm.org/toc/nejm/medical-journal  
[New issue; No digest content identified]

**npj Vaccines**  
https://www.nature.com/npjvaccines/  
[Accessed 20 May 2023]  
[No new digest content identified]

**Pediatrics**  
Volume 151, Issue 5   May 2023  
https://publications.aap.org/pediatrics/issue/151/5  
[Reviewed earlier]

**PharmacoEconomics**  
Volume 41, issue 5, May 2023  
[Reviewed earlier]

**PLoS Biology**  
https://journals.plos.org/plosbiology/  
Accessed 20 May 2023  
[No new digest content identified]

**PLoS Genetics**  
https://journals.plos.org/plosgenetics/  
Accessed 20 May 2023  
[No new digest content identified]
Determinants of Covid-19 vaccination: Evidence from the US pulse survey
Amit Roy
Research Article | published 18 May 2023 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0001927

Creating more and more new institutions may not make the world safer from pandemics
Clare Wenham
Opinion | published 17 May 2023 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0001921

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 20 May 2023)
[No new digest content identified]

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 20 May 2023)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 20 May 2023]
[No new digest content identified]

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 20 May 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
May 16, 2023 vol. 120 no. 20
https://www.pnas.org/toc/pnas/120/20
[New issue; No digest content identified]

PNAS Nexus
Volume 2, Issue 4, April 2023
https://academic.oup.com/pnasnexus/issue
Prehospital & Disaster Medicine
Volume 38 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 170  May 2023
[Reviewed earlier]

Proceedings of the Royal Society B
10 May 2023  Volume 290  Issue 1998
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 218  Pages 1-208 (May 2023)
[Reviewed earlier]

Public Health Ethics
Volume 16, Issue 1, April 2023
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 138 Issue 2, March/April 2023
https://journals.sagepub.com/toc/phrg/138/2
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 5, April 2023
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 19 Issue 2, April 2023
http://journals.sagepub.com/toc/reab/current
Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 20 May 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 43, Issue 5  Pages: 867-1091  May 2023
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 20 May 2023]
[No new digest content identified]

Science
Volume 380| Issue 6646| 19 May 2023
https://www.science.org/toc/science/current
Reviews
Science and the legal rights of nature
BY Yaffa Epstein, et al.
Jessica K. Abbott
19 May 2023
A review examines the role of science in rights-of-nature laws.

Science and Engineering Ethics
Volume 29, issue 3, June 2023
[Reviewed earlier]

Science Translational Medicine
Volume 15| Issue 696| 17 May 2023
https://www.science.org/toc/stm/current
Scientific Reports
https://www.nature.com/srep/articles?type=article
[Accessed 20 May 2023]
[No new digest content identified]

Social Science & Medicine
Volume 326 June 2023
[New issue; No digest content identified]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 20 May 2023]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 44, issue 3, June 2023
[New issue; No digest content identified]

Travel Medicine and Infectious Diseases
Volume 52 March–April 2023
[Reviewed earlier]

Tropical Medicine & International Health
Volume 28, Issue 5 Pages: i-iv, 343-418 May 2023
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 41, Issue 18 Pages 2879-3010 (2 May 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/18
Selected Content
Research article Full text access
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
Greta Santi Laurini, Nicola Montanaro, Massimiliano Broccoli, Giulia Bonaldo, Domenico Motola
Pages 2879-2886
Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States
Namrata Prasad, Charles Stoecker, Wei Xing, Bo-Hyun Cho, ... Miwako Kobayashi
Pages 2914-2921

Using geographic information system to track children and optimize immunization coverage and equity in Karachi, Pakistan
Muhammad Siddique, Sundus Iftikhar, Vijay Kumar Dharma, Mubarak Taighoon Shah, ... Subhash Chandir
Pages 2922-2931

Patterns of HPV vaccine hesitancy among catch-up generations in Japan: A descriptive study
Masaki Machida, Shigeru Inoue
Pages 2956-2960

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 20 May 2023]

Adaptation and Validation of a French Version of the Vaccination Attitudes Examination (VAX) Scale
by Margot Eisenblaetter, et al.
Vaccines 2023, 11(5), 1001; https://doi.org/10.3390/vaccines11051001
Received: 19 April 2023 / Revised: 14 May 2023 / Accepted: 17 May 2023 / Published: 19 May 2023

Abstract
Over the past decades, vaccination has proven to be largely beneficial to global health. Despite vaccine efficacy, the French population has been recently affected by more anti-vaccination attitudes and vaccine refusal, and it is therefore necessary to validate tools to study this health issue. The Vaccination Attitudes Examination scale (VAX) is a 12-item questionnaire targeting adults that assesses general attitudes towards vaccination. The aims of the study were to translate and adapt the original English version of the scale into French and to test the psychometric properties of the scale in a French-population-based sample of adults. We included 450 French speaking adults that completed the French VAX and other questionnaires to assess convergent and divergent validities. Exploratory and confirmatory factor analyses showed that the French version of the VAX replicated the factorial structure of the original scale. Moreover, it demonstrated high internal consistency, good convergent and divergent validities, and excellent temporal stability. Furthermore, scores on the scale differentiated vaccinees from non-vaccinee respondents. Results on the scale provide us with insight into factors involved in vaccine hesitancy in France, therefore allowing French authorities and policy makers to address these specific concerns and improve vaccine acceptance rates in this country.
A scoping review of behavioural science approaches and frameworks for health protection and emergency response
Alice Zelenka Martin, Dale Weston, Jo Kesten, Clare French
medRxiv 2023.05.19.23290226; doi: https://doi.org/10.1101/2023.05.19.23290226

Aim: Rapid intervention development, implementation and evaluation is required for emergency public health contexts, such as the recent COVID-19 pandemic. A novel Agile Co-production and Evaluation (ACE) framework has been developed to assist this endeavour in future public health emergencies. This scoping review aimed to map available behavioural science resources that can be used to develop and evaluate public health guidance, messaging, and interventions in emergency contexts onto components of ACE: rapid development and implementation, co-production with patients or the public including seldom heard voices from diverse communities, and inclusion of evaluation.

Closing the Pneumococcal Conjugate Vaccine (PCV) Introduction Gap: An Archetype Analysis of ‘last-mile’ countries
Preetika Banerjee, Jasmine Huber, Veronica Denti, Molly Sauer, Rose Weeks, Baldeep K. Dhaliwal, Anita Shet ashet1@jhu.edu
medRxiv 2023.05.10.23289791; doi: https://doi.org/10.1101/2023.05.10.23289791

Pneumonia remains the leading infectious cause of global childhood deaths, despite the availability of World Health Organization (WHO)-prequalified pneumococcal conjugate vaccine (PCV) products and
the evidence of their safety and efficacy for over two decades, along with financial and technical support from Gavi The Vaccine Alliance (Gavi). There are 39 remaining “last-mile” countries (33 low- and middle-income countries [LMICs] and six high-income countries) that haven’t fully included PCV in their National Immunization Programs. To address this inequitable distribution of PCV, we conducted a rapid assessment and landscaping exercise of country indicators related to barriers and facilitators for PCV decision-making, aiming to categorize countries into archetypes that could benefit from shared advocacy approaches...

**OSF Pre-prints**
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 20 May 2023]
[Provider Filter: OSF Pre-prints  Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

*We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.*

[No new digest content identified]

**Wellcome Open Research**
https://wellcomeopenresearch.org/browse/articles
[Accessed 20 May 2023]

*Selected Research*

*Review Open Access*

**A landscape analysis of the key global stakeholders working on interventions around preterm birth that improve neonatal mortality and morbidity.** [version 1; peer review: awaiting peer review] 16 May 2023
Grainne Moon, Michael English  grainnemoon4@gmail.com, Shobhana Nagraj
shobhana.nagraj@ndm.ox.ac.uk

*Abstract*

**Background**
Over a decade after the landmark ‘Born too Soon’ report, preterm birth remains a leading cause of under-five mortality. Addressing its global burden is key to meeting United Nations Sustainable Development Goal 3; to end preventable deaths of newborns and children by 2030. We conducted a landscape analysis to explore the types of organisations addressing preterm birth, highlight the scope of interventions and initiatives, and identify gaps and opportunities for shared learning.

**Methods**
We combined google searches with citation searching, and opinion of experts in child health, to identify the major global stakeholders working to improve outcomes of preterm birth, with evidence of activity since 2012. We conducted a thematic analysis and narrative synthesis of key stakeholder websites to categorise their functions and priorities, and the types of interventions they were implementing.

**Results**
A total of 38 key organisations and 28 interventions were derived from the searches. Organisations were thematically grouped into knowledge sharing (n = 15), knowledge production (n = 12), funders (n = 6), legislation and advocacy (n = 15), implementer (n = 14) and network organisations (n = 11). Interventions covered a wide scope of functions including education (n = 11), research (n = 10), resources (n = 7), legislation (n = 2), and health systems (n = 2) interventions. The majority of global
stakeholders were funded from and headquartered within high-income settings.

Discussion
There is scope for significant learning across global stakeholders, in particular to support carers in low-resource settings. Further opportunities for impact include a need for community-based initiatives and whole systems approach that address the long-term needs of preterm babies and their families, particularly in low- and middle-income countries (LMIC) settings. Greater knowledge production and funding from LMICs is needed to create contextually relevant resources and address implementation challenges.

* * * * *

Think Tanks

**Brookings** [to 20 May 2023]
http://www.brookings.edu/
* Latest Research [Selected]
No new digest content identified.

**Center for Global Development** [to 20 May 2023]
https://www.cgdev.org/
* All Research [Selected]
**CASE STUDIES**
* Facing the Pandemic of Antimicrobial Resistance: Current Actions and Future Challenges in Antibiotic Stewardship, Access, and Innovation in Brazil
  Claudio A. Mora-García et al.
  May 18, 2023
  Almost 140,000 people die with a drug-resistant bacterial infection in Brazil every year due in large part to shortcomings in access, stewardship, and innovation for antimicrobials. Brazil’s existing Productive Development Partnerships system could be modified to reduce incentives for overselling an...

* Policies and Interventions to Improve Access to Next-Generation Antimicrobials in Low- and Middle-Income Countries: India Case Study
  Parshuram Hotkar et al.
  May 18, 2023
  Antimicrobial resistance (AMR) poses a threat to global health security worldwide, and India carries one of the largest burdens of drug-resistant pathogens. The widespread misuse and overuse of antimicrobials is a major cause of the emergence and spread of resistant microorganisms. This study assess...

**Chatham House** [to 20 May 2023]
https://www.chathamhouse.org/
* Selected Analysis, Comment, Events
No new digest content identified.
Smallpox Eradication: A Model for Global Cooperation

This brief for the “Advancing Collaboration in an Era of Strategic Competition” project explores the motivations and mechanisms behind U.S.-Soviet coordination on smallpox eradication, drawing lessons for how rivals can approach collaboration on issues of shared concern.

Brief by Nellie Bristol — May 17, 2023

Kaiser Family Foundation

No new digest content identified.

McKinsey Global Institute

No new digest content identified.

ODI [Overseas Development Institute]

Changing climate, changing realities: migration in the Sahel

17 May 2023

Research reports

Pew Research Center

No new digest content identified.

Rand

No new digest content identified.

Urban Institute

No new digest content identified.
Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.